

mithra

Women's Health

Mission & Vision

Mithra is a Belgian **biotech company** dedicated to transforming **Women's Health** by offering new choices through innovation, with a focus on contraception and menopause.

Our goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.


Founders




F. Fornieri

Prof. Dr. JM Foidart

At a Glance



Worldwide Markets



Why invest?

- Breakthrough innovation with the unique hormone **Estetrol (E4)**, **a native estrogen with an improved benefit/risk profile**
- 3 late-stage potential blockbusters, including **Estelle®**, a new era in Combined Oral Contraception on the market from 2021, **Donesta®**, the next generation of Hormone Therapy and **PeriNesta®**, the first potential complete oral treatment targeting perimenopause
- **Strong IP Position** with over 35 patent families
- Commercial **partnership strategy** with leaders in women's health
- **Multiple opportunities** beyond women's health
- Worldwide specialist in **long acting drug development** using polymer technology
- **Mithra CDMO**, industry partner with specialist R&D and manufacturing capabilities for polymeric forms, injectables and hormonal tablet products

Corporate strategy


To leverage the full potential of our E4 portfolio, and to develop partnering for our development and manufacturing technology platform.

Portfolio

	Product	Therapeutical area	Phase 1	Phase 2	Phase 3	Market approval
E4	Estelle®	<i>Contraception</i>				2021
	PeriNesta®	<i>Perimenopause</i>				2023
	Donesta®	<i>Menopause</i>				2023
	COVID-19 Treatment®	<i>COVID-19</i>				2021 (conditional approval)
	Under development	<i>CNS, dermatology, oncology, etc.</i>	Various stages of non-clinical development of future E4-based pipeline			
			Formulation Clinical/BioEq.	Filing	Market approval	
COMPLEX THERAPEUTICS	Myring™	<i>Contraception</i>	Europe			commercialized
			U.S.			2021
	Zoreline®	<i>Oncology</i>				2024
	Tibelia®	<i>Menopause</i>				commercialized

Share Structure

as of December 31, 2020




Stock Information




as of December 31, 2020

Primary exchange Euronext


Ticker MITRA



Financials



Group Structure



* ex. Fund (starting 1/1/2021)

2021 Financial calendar

- 9-Mar**
2020 Annual Results
- 20-Apr**
2020 Annual Report
- 20-May**
Annual General Meeting
- 24-Sep**
2021 Half Year Results

Analyst Coverage

- > **Berenberg**
Beatrice Allen
- > **Degroof Petercam**
Benoît Louage
- > **KBC**
Lenny Van Steenhuyse
- > **Kempen**
Alexandru Cogut
- > **Kepler Cheuvreux**
Pierre-Alexandre Desir
- > **Portzamparc**
Christophe Dombu



Stay in touch!

Subscribe to our mailing list:
investors.mithra.com/en/contact/#subscribe